➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Baxter
Mallinckrodt
McKesson
AstraZeneca

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

NETSPOT Drug Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Netspot, and what generic alternatives are available?

Netspot is a drug marketed by Aaa Usa Inc and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-nine patent family members in nineteen countries.

The generic ingredient in NETSPOT is gallium dotatate ga-68. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the gallium dotatate ga-68 profile page.

DrugPatentWatch® Generic Entry Outlook for Netspot

Netspot was eligible for patent challenges on June 1, 2020.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 10, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Get Started Free

Summary for NETSPOT
International Patents:29
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 4
What excipients (inactive ingredients) are in NETSPOT?NETSPOT excipients list
DailyMed Link:NETSPOT at DailyMed
Drug patent expirations by year for NETSPOT
DrugPatentWatch® Estimated Generic Entry Opportunity Date for NETSPOT
Generic Entry Date for NETSPOT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NETSPOT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Assistance Publique - Hôpitaux de ParisPhase 3
University of Alabama at BirminghamEarly Phase 1
West Virginia UniversityPhase 2

See all NETSPOT clinical trials

US Patents and Regulatory Information for NETSPOT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aaa Usa Inc NETSPOT gallium dotatate ga-68 POWDER;INTRAVENOUS 208547-001 Jun 1, 2016 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
Aaa Usa Inc NETSPOT gallium dotatate ga-68 POWDER;INTRAVENOUS 208547-001 Jun 1, 2016 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Aaa Usa Inc NETSPOT gallium dotatate ga-68 POWDER;INTRAVENOUS 208547-001 Jun 1, 2016 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Baxter
Johnson and Johnson
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.